ARCTUREM LLC is the change and innovation expertise company led by Kevin Noble. It features his individual expertise and capabilities in advancing innovation leadership, culture and operations. It also ties into a broader network of open organizations to meet your needs for speaking, business model creation and program execution.
Kevin Noble is a strategist, scout, marketer, mentor and entrepreneur focused on enabling individuals and organizations apply disruptive technologies to achieve growth in evolving markets and fend off competitive threats.
Kevin provides expertise to organizations looking to successfully navigate the challenges of innovation, accomplish change management objectives and manage key brands in rapidly changing environments. He is an advisor to several early stage digital health and information companies (ex. DNA Compass) and a member of Open ExO, a Global Transformation Ecosystem helping organizations, institutions and people to transform and unlock abundance business models.
Kevin has been and remains active in driving adoption of disruptive technologies. In 2019-2020, he will serve as Entrepreneur-in-Residence for Singularity University in Copenhagen, Denmark and Mountain View, California. He will continue his role as mentor for startups in the SU Ventures Lab. He will also play the role of “wicked problem” Validator for the 10.10.10 program in Denver, Colorado. In the past, Kevin was the Corporate Founding Partner for Singularity University, Exponential Medicine and ARC Fusion. He was also an active partner with Rock Health, StartUp Health, HealthTech Capital and XPrize.
Kevin brings a distinguished career as a corporate entrepreneur and innovation champion. At Genentech, he founded and launched the Commercial Strategy function. As Senior Director, he led the enterprise strategic planning process, shaped the future facing agenda (including innovation), ensured competitive readiness and accelerated major change management initiatives. In four years, his teams completed >20 health innovation pilot programs and managed 13 breakthrough technologies. He played similar roles at Roche, Abbott Laboratories and Bristol-Myers Squibb Company.